Osteoblastic 11 β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure

Journal of Bone and Mineral Research

Volumn 17, Issue 6, 2002, Pages 979-986

  Cooper, Mark S ^a   Rabbitt, Elizabeth H ^a   Goddard, Philippa E ^b   Bartlett, William A ^b   Hewison, Martin ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase; Aging; Bone; Cortisol; Glucocorticoids; Osteoblasts; Osteoporosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLUCOCORTICOID; HSD11B1 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; PREDNISOLONE; PREDNISONE; PRIMER DNA; COMPLEMENTARY DNA; CORTISONE; DEXAMETHASONE; HYDROCORTISONE; MESSENGER RNA;

AGING; ARTICLE; CELL CULTURE; DRUG EFFECT; ENZYME SPECIFICITY; ENZYMOLOGY; HUMAN; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PHYSIOLOGY; ADULT; AGED; AUTOCRINE EFFECT; CALCANEUS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; FEMALE; FETUS; HUMAN CELL; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CELL; NORMAL HUMAN; OSTEOPOROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AGING; BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; GLUCOCORTICOIDS; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; OSTEOBLASTS; PREDNISOLONE; PREDNISONE; SUBSTRATE SPECIFICITY;

EID: 0035999432     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.6.979     Document Type: Article

References (43)

1. Clinical review 83: Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
2. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis
3. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
4. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis
5. Use of oral corticosteroids and risk of fractures
6. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
7. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
8. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
9. Magnitude and impact of osteoporosis and fractures
10. Age- and sex-related changes in iliac cortical bone mass and remodeling
11. Changes in quantitative bone histomorphometry in aging healthy men
12. Age-related changes of the hypothalamic-pituitary-adrenal axis: Pathophysiological correlates
13. 11β-hydroxysteroid dehydrogenase
14. Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone
15. Characterization of 11β-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines
16. Expression of 11β-hydroxysteroid dehydrogenase in rat osteoblastic cells: Pre-receptor regulation of glucocorticoid responses in bone
17. Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: An autocrine switch from glucocorticoid inactivation to activation
18. Pre-receptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase: A novel determinant of cell proliferation
19. Does central obesity reflect "Cushing's disease of the omentum"?
20. Regulation of 11 β-hydroxysteroid dehydrogenase activity in human skin fibroblasts: Enzymatic modulation of glucocorticoid action
21. 11β-hydroxysteroid dehydrogenase is an exclusive 11βreductase in primary cultures of rat hepatocytes: Effect of physicochemical and hormonal manipulations
22. Effect of growth hormone, insulin and dexamethasone on 11β-hydroxysteroid dehydrogenase activity on a primary culture of rat hepatocytes
23. Differentiation of adipose stromal cells: The roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase
24. Use of oral corticosteroids in the United Kingdom
25. Human bone cells in vitro
26. Human 11β-hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue
27. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
28. A non-isotopic method for estimating 11β-hydroxysteroid dehydrogenase activity in vivo
29. Influence of skeletal site of origin and donor age on osteoblastic cell growth and differentiation
30. Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol
31. A transgenic model of visceral obesity and the metabolic syndrome
32. 11β-hydroxysteroid dehydrogenase 1 in adipocytes: Expression is differentiation-dependent and hormonally regulated
33. Tissue- and temporal-specific regulation of 11β-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo
34. Conversion of cortisone to cortisol and prednisone to prednisolone
35. Selective inhibition of human type I 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics
36. Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome
37. Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review
38. Delivery and transport of glucocorticoids to target cells
39. Glucocorticoids and insulin resistance: Old hormones, new targets
40. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans
41. Bone loss after glucocorticoid therapy
42. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients
43. Deflazacort - An alternative to prednisolone?